Trigeminal Neuralgia Market

Market Overview:

The 7 major trigeminal neuralgia markets reached a value of US$ 234.5 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 357.8 Million by 2034, exhibiting a growth rate (CAGR) of 3.92% during 2024-2034.

The trigeminal neuralgia market has been comprehensively analyzed in IMARC's new report titled "Trigeminal Neuralgia Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Trigeminal neuralgia, also called tic douloureux, refers to a disorder that affects the trigeminal nerve, which is responsible for sending sensory information from the face to the brain. This disease is often characterized by sudden, severe, and intense facial pain (usually on one side of the face) that can last from a few seconds to several minutes. The pain can be triggered by simple actions, such as touching the face, brushing the teeth, or even talking. Individuals suffering from trigeminal neuralgia may experience muscle spasms, episodes of sharp, shooting or jabbing pain, a stabbing or electrical-type feeling, oversensitivity or uncomfortable tingling, etc. The diagnosis of this illness relies on the identification of clinical features, medical history, and a physical exam of the head and neck region. A neurological examination is further recommended, in which the healthcare provider touches and examines portions of the face to identify the location and triggering factors of the pain. Additionally, a high-resolution, thin-slice magnetic resonance imaging test that helps to rule out other causes of underlying indications is also utilized. 

The rising cases of multiple sclerosis, which can cause deterioration of the body's main protective layer around the neuron, known as the myelin sheath, are primarily driving the trigeminal neuralgia market. In addition to this, the increasing incidences of nerve compression on account of facial injury, obesity, cervical foraminal narrowing, etc., are also propelling the market growth. Furthermore, the inflating adoption of anticonvulsant drugs, including carbamazepine and gabapentin, to control pain and lessen the symptoms of the disease is acting as another significant growth-inducing factor. Apart from this, the escalating application of microvascular decompression technique for identifying any blood vessels that may be contributing to nerve compression and treating the nerve to recover and return to a normal, pain-free condition is creating a positive outlook for the market. Additionally, the emerging popularity of deep brain stimulation therapy, which involves the implantation of electrodes within specific areas of the brain to drastically improve pain and boost the quality of life in patients, is expected to drive the trigeminal neuralgia market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the trigeminal neuralgia market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for trigeminal neuralgia and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the trigeminal neuralgia market in any manner.

Time Period of the Study

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034
   

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the trigeminal neuralgia market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the trigeminal neuralgia market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current trigeminal neuralgia marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug overview
• Mechanism of action
• Regulatory status
• Clinical trial results
• Drug uptake and market performance    
   

Late-Stage Pipeline Drugs

• Drug overview
• Mechanism of action
• Regulatory status
• Clinical trial results
• Drug uptake and market performance
   

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the trigeminal neuralgia market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
• What was the country-wise size of the trigeminal neuralgia market across the seven major markets in 2023 and what will it look like in 2034?
• What is the growth rate of the trigeminal neuralgia market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of prevalent cases (2018-2034) of trigeminal neuralgia across the seven major markets?
• What is the number of prevalent cases (2018-2034) of trigeminal neuralgia by age across the seven major markets?
• What is the number of prevalent cases (2018-2034) of trigeminal neuralgia by gender across the seven major markets?
• What is the number of prevalent cases (2018-2034) of trigeminal neuralgia by type across the seven major markets?
• How many patients are diagnosed (2018-2034) with trigeminal neuralgia across the seven major markets?
• What is the size of the trigeminal neuralgia patient pool (2018-2023) across the seven major markets?
• What would be the forecasted patient pool (2024-2034) across the seven major markets?
• What are the key factors driving the epidemiological trend of trigeminal neuralgia?
• What will be the growth rate of patients across the seven major markets?
   

Trigeminal Neuralgia: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for trigeminal neuralgia drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the trigeminal neuralgia market?
• What are the key regulatory events related to the trigeminal neuralgia market?
• What is the structure of clinical trial landscape by status related to the trigeminal neuralgia market?
• What is the structure of clinical trial landscape by phase related to the trigeminal neuralgia market?
• What is the structure of clinical trial landscape by route of administration related to the trigeminal neuralgia market?